Management of Pemphigus in COVID-19 Pandemic Era; a Review Article

The novel coronavirus is rapidly spreading around the world. Since the public announcement of the COVID-19outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take im-munosuppressive drugs. In this paper, we review the literature about the common treatment of pemphigus witha focus on the lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV ) on COVID-19 isnot clear. We also do not have data on the impact of this autoimmune disease, which may involve the mucousmembranes, on the acquisition or course of COVID-19. We are currently in the midst of a pandemic and eval-uating the effect of COVID-19 on the population of susceptible patients suffering from auto-immune diseaseslike pemphigus is essential. The evidence on best ways to manage patients with underlying conditions, such aspemphigus, during the outbreak of COVID-19 is evolving and the data is updated every day.